NA
AUPH icon

Navellier & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Navellier & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
257,142
+142,206
+124% +$2.27M 0.35% 64
2026
Q1 		$1.7M Buy
114,936
+3,250
+3% +$47.5K 0.18% 115
2025
Q4 		$1.78M Buy
111,686
+27,906
+33% +$396K 0.2% 109
2025
Q3 		$926K Buy
+83,780
New +$915K 0.09% 191

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navellier & Associates's AUPH Position: Q2 2026 in Review

Navellier & Associates increased its Aurinia Pharmaceuticals (AUPH) stake by 124% in Q2 2026, buying an estimated $2.27M and bringing the position to 257,142 shares worth $4.36M. The position accounts for 0.35% of the portfolio, ranked #64.

Navellier & Associates first reported a position in AUPH in Q3 2025 and has held it in 4 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Navellier & Associates held 257,142 shares of Aurinia Pharmaceuticals worth $4.36M as of Q2 2026.
  • Navellier & Associates bought 142,206 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Aurinia Pharmaceuticals made up 0.35% of Navellier & Associates's portfolio in Q2 2026, its #64 holding.
  • Navellier & Associates first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.